Tenapanor-A Novel Approach for Management of Hyperphosphatemia in End Stage Renal Disease: A Clinical Study Aggregate Review
CLINICAL STUDY AGGREGATE REPORT
Abstract
The critical importance of phosphate regulation in chronic kidney disease (CKD) has been well understood for decades. But new findings, frequently applicable to routine medical care, continue to evolve. Poor health outcomes, greater morbidity, lowered quality of life, and a higher death rate from cardiovascular disease are all linked to the development of CKD-bone mineral ailment. Increased blood phosphate levels are linked to an increased risk of mortality in hemodialysis patients due to changes in phosphate breakdown and declining renal function as CKD advances.In this setting, according to CKD-mineral bone disease recommendations, it is critical to regulate serum phosphate levels in patients with CKD-mineral bone problem. If dialysis and dietary intervention fail to control blood phosphate levels, the use of phosphate binders is advised. Although phosphate binders are successful in lowering blood phosphate levels by actively binding to dietary phosphate, certain individuals have adverse effects that may restrict their use.These medications also have a significant pill load, which might result in poor treatment compliance. Tenapanor, a novel medication, works by inhibiting the sodium/hydrogen exporter isoform 3 (NHE3), which lowers intestinal phosphate absorption primarily by decreasing passive paracellular phosphate flow. Tenapanor also reduces the expression of the sodium phosphorus 2b transport protein (NaPi2b), which limits active transcellular phosphate absorption compensation. This is considered to be more effective phosphorous absorption regulator and a better target for tailored medication therapy. This clinical study aggregate report explores the currently published studies that have evaluated Tenapanor for the treatment of hyperphosphatemia in end stage renal disease patients on haemodialysis.
Keywords: Tenapanor, phosphate binding agents, hyperphosphatemia, chronic kidney disease, phosphate control, phosphate binders, phosphate absorption, phosphate absorbtion inhibitor.
Keywords:
Tenapanor, phosphate binding agents, hyperphosphatemia, chronic kidney disease, phosphate control, phosphate binders, phosphate absorption, phosphate absorbtion inhibitorDOI
https://doi.org/10.22270/jddt.v14i1.6336References
Naber T, Purohit S. Chronic Kidney Disease: Role of Diet for a Reduction in the Severity of the Disease. Nutrients. 2021 Sep 19;13(9):3277. https://doi.org/10.3390/nu13093277 PMid:34579153 PMCid:PMC8467342
Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998 https://doi.org/10.1053/ajkd.1998.v31.pm9531176 PMid:9531176
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004 https://doi.org/10.1097/01.ASN.0000133041.27682.A2 PMid:15284307
Toussaint ND, Pedagogos E, Tan SJ, Badve SV, Hawley CM, Perkovic V, et al.: Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. Nephrology (Carlton) 17: 433-444, 2012 https://doi.org/10.1111/j.1440-1797.2012.01618.x PMid:22574672
Salomo L, Kamper AL, Poulsen GM, Poulsen SK, Astrup A, Rix M. Habitual dietary phosphorus intake and urinary excretion in chronic kidney disease patients: a 3-day observational study. Eur J Clin Nutr. 2017 Jun;71(6):798-800. https://doi.org/10.1038/ejcn.2016.247 PMid:27966564
Rastogi A, Bhatt N, Rossetti S, Beto J. Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm. J Ren Nutr. 2021 Jan;31(1):21-34. https://doi.org/10.1053/j.jrn.2020.02.003 PMid:32386937
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017 Jul;7(1):1-59. Epub 2017 Jun 21. Erratum in: Kidney Int Suppl (2011). 2017 Dec;7(3):e1. PMID: 30675420; PMCID: PMC6340919. https://doi.org/10.1016/j.kisu.2017.10.001
Covic A, Rastogi A. Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol. 2013 Jul 18;14:153. https://doi.org/10.1186/1471-2369-14-153 PMid:23865421 PMCid:PMC3728082
PhosLo gelcaps (calcium acetate): 667 mg [prescribing information]. Fresenius Medical Care North America, 2011.
VELPHORO (sucroferric oxyhydroxide) [prescribing information]. Fresenius Medical Care North America, 2013.
FOSRENAL (lanthanum carbonate) [prescribing information]. Shire US Inc., 2016.
AURYXIA (ferric citrate) tablets [prescribing information]. Keryx Biopharmaceuticals Inc., 2017.
RENVELA (sevelamer carbonate) [prescribing information]. Genzyme Corp., 2020.
Suki WN, Moore LW. Phosphorus Regulation in Chronic Kidney Disease. Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4 Suppl):6-9. https://doi.org/10.14797/mdcj-12-4s1-6 PMid:28298956 PMCid:PMC5347182
Davis GR, Zerwekh JE, Parker TF, Krejs GJ, Pak CY, Fordtran JS. Absorption of phosphate in the jejunum of patients with chronic renal failure before and after correction of vitamin D deficiency. Gastroenterology. 1983 Oct;85(4):908-16. https://doi.org/10.1016/0016-5085(83)90443-2 PMid:6688402
King AJ, Siegel M, He Y, Nie B, Wang J, Koo-McCoy S, Minassian NA, Jafri Q, Pan D, Kohler J, Kumaraswamy P, Kozuka K, Lewis JG, Dragoli D, Rosenbaum DP, O'Neill D, Plain A, Greasley PJ, Jönsson-Rylander AC, Karlsson D, Behrendt M, Strömstedt M, Ryden-Bergsten T, Knöpfel T, Pastor Arroyo EM, Hernando N, Marks J, Donowitz M, Wagner CA, Alexander RT, Caldwell JS. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018 Aug 29;10(456):eaam6474. https://doi.org/10.1126/scitranslmed.aam6474 PMid:30158152 PMCid:PMC6454550
Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. J Am Soc Nephrol. 2019 Apr;30(4):641-652. https://doi.org/10.1681/ASN.2018080832 PMid:30846557 PMCid:PMC6442342
Rosenbaum DP, Yang Y. Efficacy of tenapanor for the control of serum phosphorus in patients with chronic kidney disease on dialysis: novel mechanism of action allows for both monotherapy and dual mechanism approaches. Paper presented at the American Society of Nephrology (ASN) Kidney Week [Virtual meetihng], October 20-25, 2020
Chertow GM, Yang Y, Rosenbaum DP. Paper presented at the Long-term safety and efficacy of tenapanor for the control of serum phosphorus in patients with chronic kidney disease on dialysis. Presented at the American Society of Nephrology (ASN) Kidney Week 2020 [Virtual meeting], October 20-25, 2020.
Saurette M, Alexander RT. Intestinal phosphate absorption: the paracellular pathway predominates? Exp Biol Med(Maywood). 2019May;244(8):646-54. https://doi.org/10.1177/1535370219831220 PMid:30764666 PMCid:PMC6552399
Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2). Am J Gastroenterol. 2021 Jun 1;116(6):1294-1303. https://doi.org/10.14309/ajg.0000000000001056 PMid:33337659 PMCid:PMC8183489
Shigematsu T, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia. Am J Nephrol. 2021;52(6):496-506. https://doi.org/10.1159/000516156 PMid:34098559 PMCid:PMC8491508
Rosenbaum DP, Yan A, Jacobs JW. Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers. Clin Drug Investig. 2018 Apr;38(4):341-351. https://doi.org/10.1007/s40261-017-0614-0 PMid:29363027 PMCid:PMC5856883
Johansson S, Rosenbaum DP, Ahlqvist M, Rollison H, Knutsson M, Stefansson B, Elebring M. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions. Clin Pharmacol Drug Dev. 2017 Sep;6(5):466-475. https://doi.org/10.1002/cpdd.346 PMid:28301096 PMCid:PMC5599994
Spencer, Andrew G., et al. "Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans." Science translational medicine 6.227 (2014): 227ra36-227ra36.
Pergola PE, Rosenbaum DP, Yang Y, Chertow GM. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY). J Am Soc Nephrol. 2021 Jun 1;32(6):1465-1473. https://doi.org/10.1681/ASN.2020101398 PMid:33766811 PMCid:PMC8259655
Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999 Apr;33(4):694-701. https://doi.org/10.1016/S0272-6386(99)70221-0 PMid:10196011
Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Åstrand M, Johansson S, Knutsson M, Langkilde AM, Chertow GM. Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis. J Am Soc Nephrol. 2017 Jun;28(6):1933-1942. https://doi.org/10.1681/ASN.2016080855 PMid:28159782 PMCid:PMC5461797
Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010 Apr 8;362(14):1312-24. https://doi.org/10.1056/NEJMra0912522 PMid:20375408
Fissell RB, Karaboyas A, Bieber BA, Sen A, Li Y, Lopes AA, Akiba T, Bommer J, Ethier J, Jadoul M, Pisoni RL, Robinson BM, Tentori F. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS. Hemodial Int. 2016 Jan;20(1):38-49. https://doi.org/10.1111/hdi.12315 PMid:25975222 PMCid:PMC4644509
NIH U.S. National Library of Medicine. A long-term study to evaluate the ability of tenapanor alone or in combination with sevelamer to treat to goal serum phosphorus in patients with end-stage kidney disease on dialysis (NORMALIZE). Accessed June 8, 2021. https://clinicaltrials.gov/ct2/show/NCT03988920?term=nct03988920&draw=2&rank=1
Melville NA. Medscape. FDA Rejects tenapanor for control of phosphorus in kidney disease. Accessed October 12, 2021 https://www.medscape.com/viewarticle/956066
Johansson S, Rosenbaum DP, Knutsson M,Leonsson-Zachrisson, M. A phase 1 study of the safety, tolerability, pharmacodynamics and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol. 2017Jun;21(3):407-16. https://doi.org/10.1007/s10157-016-1302-8 PMid:27368672 PMCid:PMC5486465
King AJ, Kohler J, Fung C, Jiang Z, Quach A, Kumaraswamy P, Chertow GM, Rosenbaum DP. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats. Am J Physiol Renal Physiol. 2021 Jan 1;320(1):F133-F144. https://doi.org/10.1152/ajprenal.00137.2020 PMid:33283643
King AJ, Siegel M, He Y, Nie B, Wang J, Koo-McCoy S, Minassian NA, Jafri Q, Pan D, Kohler J, Kumaraswamy P, Kozuka K, Lewis JG, Dragoli D, Rosenbaum DP, O'Neill D, Plain A, Greasley PJ, Jönsson-Rylander AC, Karlsson D, Behrendt M, Strömstedt M, Ryden-Bergsten T, Knöpfel T, Pastor Arroyo EM, Hernando N, Marks J, Donowitz M, Wagner CA, Alexander RT, Caldwell JS. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018 Aug 29;10(456):eaam6474. https://doi.org/10.1126/scitranslmed.aam6474 PMid:30158152 PMCid:PMC6454550
Johansson S, Leonsson-Zachrisson M, Knutsson M, et al. Preclinical and healthy volunteer studies of potential drug-drug interactions between phosphate binders. Clin Pharmacol Drug Dev. 2017 Sep;6(5):448-56. https://doi.org/10.1002/cpdd.307 PMid:27654985 PMCid:PMC5599948
Published
Abstract Display: 750 
PDF Downloads: 507 PDF Downloads: 151 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.